Bladder Cancer Coverage from Every Angle

Sumanta K. Pal, MD: Does Adding Berzosertib to Chemotherapy Improve Outcomes in Urothelial Carcinoma?

Posted: Tuesday, June 15, 2021

Sumanta K. Pal, MD, of City of Hope, discusses the clinical implications of findings from a phase II study that showed no improvement in progression-free survival with the addition of berzosertib, an ATR inhibitor, to platinum-based chemotherapy in patients with advanced urothelial carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.